Abstracts tagged "joint destruction"

Abstract Number: 1199 • 2014 ACR/ARHP Annual Meeting
Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort
Rik Schelbergen¹, Wouter de Munter², Martijn van den Bosch³, Floris Lafeber⁴, Annet Sloetjes³, Thomas Vogl⁵, Johannes Roth⁵, Peter M. van der Kraan⁶, Arjen B. Blom³, Wim B van den Berg³ and Peter L. van Lent³, ¹Radboud university medical center, Nijmegen, Netherlands, ²Experimental rheumatology, Radboud university medical center, Nijmegen, Netherlands, ³Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ⁴Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁶Experimental Rheumatology (272), Radboud university medical center, Nijmegen, Netherlands
Background/Purpose The main pathological feature of osteoarthritis (OA) is degradation of the articular cartilage. Other important hallmarks include subclinical inflammation of the synovium and ectopic…
Abstract Number: 1123 • 2014 ACR/ARHP Annual Meeting
Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose Patients with rheumatoid arthritis (RA) have a higher prevalence of dyslipidemia than healthy individuals. Since RA is a chronic inflammatory disease, an inflammatory response…
Abstract Number: 513 • 2014 ACR/ARHP Annual Meeting
Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics
Yukio Yonemoto, Koichi Okamura, Tetsuya Kaneko, Chisa Okura and Kenji Takagishi, Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Japan
Background/Purpose The assessment of joint destruction in rheumatoid arthritis (RA) patients being treated with biologics is normally mainly carried out for small joints. There are…
Abstract Number: 125 • 2014 ACR/ARHP Annual Meeting
PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World
Maasa Hama¹, Yumiko Sugiyama¹, Naomi Tsuchida¹, Yosuke Kunishita¹, Daiga Kishimoto¹, Reikou Kamiyama¹, Kaoru Minegishi-Takase¹, Ryusuke Yoshimi¹, Yohei Kirino², Mitsuhiro Takeno³, Atsuhisa Ueda¹ and Yoshiaki Ishigatsubo¹, ¹Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ²Yokohama City University Graduate School of Medicine, Yokohama, Japan, ³Clinical Laboratory Department, Yokohama City University Hospital, Yokohama, Japan
Background/Purpose: Biologic DMARD (biologics) therapy for rheumatoid arthritis (RA) strongly suppresses joint destruction regardless of its efficacy for disease activity. On the contrary power Doppler…
Abstract Number: 119 • 2014 ACR/ARHP Annual Meeting
Sonographic Evaluation of the Fifth Metatarsophalangeal Joint Erosion in Rheumatoid Arthritis
Nevsun Inanc¹, Gulsen Ozen¹, Sibel Z. Aydin², Esen Kasapoglu Gunal³ and Haner Direskeneli¹, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Department of Rheumatology, Koc University Faculty of Medicine, Istanbul, Turkey, ³Department of Rheumatology, Goztepe Medeniyet University Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Joint erosions in RA correlate with structural damage progression and functional capacity. Therefore, detection and the follow-up of erosions are of paramount importance for…
Abstract Number: 174 • 2013 ACR/ARHP Annual Meeting
Genetic Association On Disease Severity In Rheumatoid Arthritis: A Validation Study In Japanese Patients
Shinji Yoshida¹, Katsunori Ikari¹, Koichiro Yano¹, Yoshiaki Toyama², Atsuo Taniguchi³, Hisashi Yamanaka¹ and Shigeki Momohara³, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Department of Orthopaedic Surgery, Keio University School of Medicine, Tokyo, Japan, ³Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: The disease severity of rheumatoid arthritis (RA) is objectively measured by radiographic joint destruction, which is reflective of the cumulative burden of inflammation. Recently,…
Abstract Number: 1726 • 2013 ACR/ARHP Annual Meeting
Survivin Inhibition Disturbs Bcl-6 and Blimp-1 Control Of Lymphocyte Maturation and Alleviates Antigen-Induced Arthritis
Mattias Svensson¹, Karin Andersson¹, Malin Erlandsson¹, Ing-Marie Jonsson² and Maria Bokarewa¹, ¹Rheumatology and Inflammation Research, University of Gothenburg, Gothenburg, Sweden, ²Department of Rheumatology and Inflammation Research, Göteborgs University, Göteborg, Sweden
Background/Purpose: Survivin is a proto-oncogene known to regulate cell division and apoptosis. In patients with rheumatoid arthritis, survivin has emerged as an independent predictor of…
Abstract Number: 1457 • 2013 ACR/ARHP Annual Meeting
Inhibitory Effect Of Abatacept On Joint Damage In Rheumatoid Arthritis Patients With Or Without Concomitant Methotrexate: A Retrospective Multicenter Analysis Of 12 Months Of Abatacept Treatment In Routine Clinical Practice
Isao Matsushita¹, Hiraku Motomura¹, Eiko Seki¹ and Tomoatsu Kimura², ¹Department of Orthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan, ²Department of rthopaedic Surgery, Faculty of Medicine, University of Toyama, Toyama, Japan
Background/Purpose: Abatacept is approved for use with or without methotrexate (MTX). The purpose of this study was to clarify the inhibitory effect of abatacept on…
Abstract Number: 1453 • 2013 ACR/ARHP Annual Meeting
Repeated High Or Low Multi-Biomarker Disease Activity (VECTRA^® DA Algorithm) Scores Associated With Radiographic Outcomes In Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors
Shintaro Hirata¹, Wanying Li², Nadine A. Defranoux², Rebecca Bolce², Eric H. Sasso², Satoshi Kubo¹, Shunsuke Fukuyo¹, Kentaro Hanami³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Yoshiya Tanaka¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²Crescendo Bioscience Inc., South San Francisco, CA, ³The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
Background/Purpose: A novel multi-biomarker disease activity (MBDA) score that is based on the serum concentrations of 12 biomarkers has been shown to correlate with clinical…
Abstract Number: 79 • 2013 ACR/ARHP Annual Meeting
Synovial Activation In Experimental OA Drives Immuno suppressive Effects Of Adipose-derived Stem Cells After Local Administration and Protects Against Chondrogenesis In Ligaments
Peter L.E.M. van Lent¹, Rik Schelbergen¹, Menno C. ter Huurne², Arjen B. Blom¹, Johannes Roth³, Thomas Vogl⁴, Christian Jorgensen⁵ and Wim B. van den Berg⁶, ¹Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Immunology, Institute of Immunology University of Muenster, Muenster, Germany, ⁴Institute of Immunology, University of Muenster, Muenster, Germany, ⁵Department of therapy & Immuno-Rhumatology, Inserm U844, CHU saint-Eloi, Université Montpellier 1, CHU Lapeyronie, Montpellier, France, ⁶Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: A substantial subpopulation of patients with early osteoarthritis (OA) show a thickened synovial lining layer comprising macrophages expressing an activated phenotype (reflected by production of…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 2092 • 2012 ACR/ARHP Annual Meeting
No Significant Effect of Hepatitis B Virus Infection On Disease Activity, Synovitis or Joint Destruction in Rheumatoid Arthritis
Chan Juan Zou, Yan Hua Li, Ying Qian Mo, Lang Jing Zhu, Dong Hui Zheng, Jian Da Ma, Xia Ouyang and Lie Dai, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: The prevalence of chronic hepatitis B virus (HBV) infection is high in China. 4% patients with HBV infection can present with polyarthritis and positive…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].